<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01906229</url>
  </required_header>
  <id_info>
    <org_study_id>959521891</org_study_id>
    <nct_id>NCT01906229</nct_id>
  </id_info>
  <brief_title>Lung and Systemic Inflammation in the Critically Ill Patient</brief_title>
  <official_title>Acute Pulmonary and Systemic Inflammation in Mechanically Ventilated Intensive Care Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute respiratory distress syndrome (ARDS) is a devastating form of acute lung inflammation,&#xD;
      that may be caused by a variety of insults with pulmonary and systemic infectious disease&#xD;
      being the most common predisposing factor. Sepsis, on the other hand, represents the systemic&#xD;
      inflammatory response to an invading pathogen, which may inflict damage upon the host through&#xD;
      organ dysfunction. ARDS and sepsis are heterogenous clinical conditions that have a high&#xD;
      mortality, and both diseases involve a complex interplay of different inflammatory mediators&#xD;
      and cell types. It has been suggested that locally released inflammatory mediators pass from&#xD;
      the lungs into the bloodstream following ARDS, triggering systemic inflammation. Conversely,&#xD;
      it is possible that severe systemic inflammation may lead to ARDS by an influx of&#xD;
      inflammatory mediators from the bloodstream to the lungs. However, the time course and the&#xD;
      possible pathways for this transmission of disease have yet to be established.&#xD;
&#xD;
      Investigators hypothesize that:&#xD;
&#xD;
        1. Primary systemic inflammation is followed by a secondary pulmonary inflammatory response&#xD;
&#xD;
        2. Primary pulmonary inflammation is followed by a secondary systemic inflammatory response&#xD;
&#xD;
        3. Both primary and secondary inflammatory responses are characterized by the appearance of&#xD;
           pro-inflammatory cytokines, inflammatory cells and production of collagen-like proteins&#xD;
           (termed 'lectins')&#xD;
&#xD;
        4. The inflammatory response is most pronounced in the primary afflicted compartment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment and therefore not possible to reach the estimated enrollment&#xD;
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-a) bioactivity</measure>
    <time_frame>Day one</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-a) bioactivity</measure>
    <time_frame>Day three</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-a) bioactivity</measure>
    <time_frame>Day seven</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-a) bioactivity</measure>
    <time_frame>Day fourteen</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin (IL)-6</measure>
    <time_frame>Day one</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mannose binding lectin (MBL)</measure>
    <time_frame>Day one</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ficolin-1,2,3</measure>
    <time_frame>Day one</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Acute Respiratory Distress Syndrome (ARDS)</condition>
  <condition>Systemic Inflammatory Response Syndrome (SIRS)</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Acute respiratory distress syndrome (ARDS)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic inflammatory response syndrome (SIRS)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ARDS+SIRS</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive care unit&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Mechanically ventilated&#xD;
&#xD;
          -  &lt; 48 hours after admission to the Intensive Care Unit&#xD;
&#xD;
        Specific:&#xD;
&#xD;
        -ARDS: acute (&lt; 1 week) respiratory failure, characterized by hypoxemia (PaO2/FiO2 &lt; 300&#xD;
        mmHg/40kPa), and bilateral infiltrates on x-ray or CT of thorax, that can not be explained&#xD;
        by heart failure og overhydration.&#xD;
&#xD;
        OR&#xD;
&#xD;
        - SIRS (two of the following): Temperature &gt; 38°C or &lt; 36°C, heart rate &gt; 90/min,&#xD;
        respiratory frequency &gt; 20 or PaCO2 &lt; 4.2 kPa, leukocytosis (&gt; 12x10^9/L) or leukopenia (&lt;&#xD;
        4x10^9/L)&#xD;
&#xD;
        OR&#xD;
&#xD;
        ARDS + SIRS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        One lung ventilation; Tube size &lt; 8.0 mm; INR &gt; 1.5 or thrombocytes &lt; 40x10^9/L;&#xD;
        Intracranial hypertension; Malignant arrythmias&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Intensive Care Unit, 4131, Rigshospitalet</name>
      <address>
        <city>Copenhagen Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>July 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <last_update_submitted>December 9, 2018</last_update_submitted>
  <last_update_submitted_qc>December 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Ronni R. Plovsing</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

